Tags

Type your tag names separated by a space and hit enter

Vaccine and Therapeutic Options To Control Chikungunya Virus.
Clin Microbiol Rev. 2018 01; 31(1)CM

Abstract

Beginning in 2004, chikungunya virus (CHIKV) went from an endemic pathogen limited to Africa and Asia that caused periodic outbreaks to a global pathogen. Given that outbreaks caused by CHIKV have continued and expanded, serious consideration must be given to identifying potential options for vaccines and therapeutics. Currently, there are no licensed products in this realm, and control relies completely on the use of personal protective measures and integrated vector control, which are only minimally effective. Therefore, it is prudent to urgently examine further possibilities for control. Vaccines have been shown to be highly effective against vector-borne diseases. However, as CHIKV is known to rapidly spread and generate high attack rates, therapeutics would also be highly valuable. Several candidates are currently being developed; this review describes the multiple options under consideration for future development and assesses their relative advantages and disadvantages.

Authors+Show Affiliations

Division of Vector-Borne Diseases, Centers for Diseases Control and Prevention, Fort Collins, Colorado, USA APowers@cdc.gov.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

29237708

Citation

Powers, Ann M.. "Vaccine and Therapeutic Options to Control Chikungunya Virus." Clinical Microbiology Reviews, vol. 31, no. 1, 2018.
Powers AM. Vaccine and Therapeutic Options To Control Chikungunya Virus. Clin Microbiol Rev. 2018;31(1).
Powers, A. M. (2018). Vaccine and Therapeutic Options To Control Chikungunya Virus. Clinical Microbiology Reviews, 31(1). https://doi.org/10.1128/CMR.00104-16
Powers AM. Vaccine and Therapeutic Options to Control Chikungunya Virus. Clin Microbiol Rev. 2018;31(1) PubMed PMID: 29237708.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Vaccine and Therapeutic Options To Control Chikungunya Virus. A1 - Powers,Ann M, Y1 - 2017/12/13/ PY - 2017/12/15/entrez PY - 2017/12/15/pubmed PY - 2018/5/18/medline KW - chikungunya KW - therapeutics KW - vaccine JF - Clinical microbiology reviews JO - Clin Microbiol Rev VL - 31 IS - 1 N2 - Beginning in 2004, chikungunya virus (CHIKV) went from an endemic pathogen limited to Africa and Asia that caused periodic outbreaks to a global pathogen. Given that outbreaks caused by CHIKV have continued and expanded, serious consideration must be given to identifying potential options for vaccines and therapeutics. Currently, there are no licensed products in this realm, and control relies completely on the use of personal protective measures and integrated vector control, which are only minimally effective. Therefore, it is prudent to urgently examine further possibilities for control. Vaccines have been shown to be highly effective against vector-borne diseases. However, as CHIKV is known to rapidly spread and generate high attack rates, therapeutics would also be highly valuable. Several candidates are currently being developed; this review describes the multiple options under consideration for future development and assesses their relative advantages and disadvantages. SN - 1098-6618 UR - https://www.unboundmedicine.com/medline/citation/29237708/full_citation L2 - http://cmr.asm.org/cgi/pmidlookup?view=long&pmid=29237708 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.